Moderna said Thursday that its vaccine is 93% effective through six months after receiving the second dose. In a news release, the company added that it tested three booster shots in phase 2 of its ...
An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.
After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.
A new preprint study suggests that Moderna’s COVID-19 vaccine may be significantly more effective against symptomatic disease from the delta variant compared to Pfizer-BioNTech’s vaccine, while the ...
The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute that had blocked the company’s application for the first-of-its-kind shot.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results